Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from AddLife AB ( ($SE:ALIF.B) ).
AddLife AB reported a significant improvement in margins and profit for the first half of 2025, driven by strong growth in Labtech and steady demand in Medtech. The company’s strategic acquisitions, including Edge Medical Ltd., have further bolstered its performance, with a 39% increase in profit for the quarter and a 63% rise in profit after tax for the first half of the year, indicating a positive trajectory for stakeholders.
The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK178.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.
More about AddLife AB
AddLife AB operates in the life sciences industry, focusing on providing products and services in the Labtech and Medtech sectors. The company is committed to enhancing its product portfolios and maintaining cost control to improve margins and support growth.
Average Trading Volume: 189,912
Current Market Cap: SEK22.45B
See more insights into ALIF.B stock on TipRanks’ Stock Analysis page.